AnuragRelanMD

Family Medicine • Manhattan Beach, CA

Medical Director, Pharming NV

Join to view full profile

Dr. Relan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Relan's full profile

Already have an account?

Office
1010 N Sepulveda Blvd
Manhattan Beach, CA 90266
Phone+1 310-376-6262
Is this information wrong?

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Family Medicine, 1999 - 2002
David Geffen School of Medicine at UCLAClass of 1999
UCLAMPH, Health Services, 1997 - 1998
UC Berkeley BA, Economics, 1990 - 1994

Certifications & Licensure

CA State Medical License 2001 - 2024
American Board of Family Medicine Family Medicine

Clinical Trials

Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema Start of enrollment: 2005 Jul 01
Completed
Phase 2, Phase 3
Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema Start of enrollment: 2003 Jun 01
Completed
Phase 2
Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema Start of enrollment: 2004 Apr 01
Completed
Phase 2, Phase 3
Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema Start of enrollment: 2004 Jun 01
Completed
Phase 3
Recombinant Human C1 Inhibitor for the Treatment of Early Antibody-Mediated Rejection in Renal Transplantation Start of enrollment: 2010 Dec 01
Withdrawn
Phase 2
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks Start of enrollment: 2011 Jan 01
Completed
Phase 3
Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients Start of enrollment: 2012 Jan 17
Completed
Phase 2
C1 Inhibitor Registry in the Treatment of Hereditary Angioedema (HAE) Attacks Start of enrollment: 2011 Jul 01
Recruiting
Join now to see all

Publications & Presentations

PubMed

3 citations
Interim analysis: Open-label extension study of leniolisib for patients with APDS.
V Koneti Rao, Elaine Kulm, Anna Šedivá, Alessandro Plebani, Catharina Schuetz, Anna Shcherbina, Virgil A Dalm, Antonino Trizzino, Yulia Zharankova, Sharon Webster, Ala...> ;The Journal of Allergy and Clinical Immunology. 2024 Jan 1
19 citations
A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndrome.
V Koneti Rao, Sharon Webster, Anna Šedivá, Alessandro Plebani, Catharina Schuetz, Anna Shcherbina, Niall Conlon, Tanya Coulter, Virgil A Dalm, Antonino Trizzino, Yulia...> ;Blood. 2023 Mar 2
2 citations
Recombinant human C1 esterase inhibitor for hereditary angioedema attacks: A European registry
Anna Valerieva, Maria Staevska, Vesna Grivcheva-Panovska, Milos Jesenak, Kinga Viktória Kőhalmi, Katarina Hrubiskova, Andrea Zanichelli, Luca Bellizzi, Anurag Relan, R...> ;The World Allergy Organization Journal. 2021 Apr 1
Population pharmacokinetics of recombinant human C1 esterase inhibitor in children with hereditary angioedema.
Siobhan Hayes, Colm Farrell, Anurag Relan, John Anderson> ;Annals of Allergy, Asthma & Immunology. 2021 Feb 17
3 citations
Modeling Cost-Effectiveness of On-Demand Treatment for Hereditary Angioedema Attacks.
Jonathan A. Bernstein, Christopher Tyson, Anurag Relan, Philippe Adams, Raf Magar> ;Journal of Managed Care & Specialty Pharmacy. 2020 Feb 1
10 citations
Safety of recombinant human C1 esterase inhibitor for hereditary angioedema attacks during pregnancy
Dumitru Moldovan, Jonathan A. Bernstein, Roman Hakl, Grzegorz Porebski, Kimberly Poarch, William R. Lumry, Anurag Relan> ;The Journal of Allergy and Clinical Immunology. in Practice. 2019 Nov 1
13 citations
Recombinant human C1 esterase inhibitor treatment for hereditary angioedema attacks in children
Avner Reshef, Vesna Grivcheva-Panovska, Aharon Kessel, Shmuel Kivity, Maria Klimaszewska-Rembiasz, Dumitru Moldovan, Henriette Farkas, Vaclava Gutova, Stephen Fritz, A...> ;Pediatric Allergy and Immunology. 2019 Aug 1
7 citations
Efficacy of recombinant human C1 esterase inhibitor across anatomic locations in acute hereditary angioedema attacks.
James W. Baker, Jonathan A. Bernstein, Joseph R. Harper, Anurag Relan, Marc A. Riedl> ;Allergy and Asthma Proceedings. 2018 Sep 28
1 citations
C1 esterase inhibitor concentrates and attenuated androgens - Authors' reply.
Marc A. Riedl, Anurag Relan, Joseph R. Harper, Marco Cicardi> ;Lancet. 2018 Apr 7
52 citations
Recombinant human C1 esterase inhibitor for prophylaxis of hereditary angio-oedema: a phase 2, multicentre, randomised, double-blind, placebo-controlled crossover trial
Marc A. Riedl, Vesna Grivcheva-Panovska, Dumitru Moldovan, James R. Baker, William H. Yang, Bruno Giannetti, Avner Reshef, Sladjana Andrejevic, Richard F. Lockey, Roma...> ;Lancet. 2017 Sep 30
9 citations
Sustained response of recombinant human C1 esterase inhibitor for acute treatment of hereditary angioedema attacks
Jonathan A. Bernstein, Anurag Relan, Joseph R. Harper, Marc A. Riedl> ;Annals of Allergy, Asthma & Immunology. 2017 Apr 1
55 citations
Angioedema attacks in patients with hereditary angioedema : Local manifestations of a systemic activation process
Zonne L. M. Hofman, Anurag Relan, Sacha Zeerleder, Christian Drouet, Bruce L. Zuraw, C. Erik Hack> ;The Journal of Allergy and Clinical Immunology. 2016 Aug 1
2 citations
Allergenicity and safety of recombinant human C1 esterase inhibitor in patients with allergy to rabbit or cow's milk
Mignon T. van den Elzen, Harmieke van Os-Medendorp, Heike Röckmann-Helmbach, Els van Hoffen, Ans F.M. Lebens, Helma van Doorn, Rob J.B. Klemans, Carla A.F.M. Bruijnzee...> ;The Journal of Allergy and Clinical Immunology. 2016 Aug 1
22 citations
Hereditary Angioedema Attacks : Local Swelling at Multiple Sites
Zonne L. M. Hofman, Anurag Relan, C. Erik Hack> ;Clinical Reviews in Allergy & Immunology. 2016 Feb 1
57 citations
Elevated D-dimers in attacks of hereditary angioedema are not associated with increased thrombotic risk.
Avner Reshef, Andrea Zanichelli, Hilary Longhurst, Anurag Relan, C. E. Hack> ;Allergy. 2015 May 1
29 citations
Recombinant human-C1 inhibitor is effective and safe for repeat hereditary angioedema attacks
H. Henry Li, Dumitru Moldovan, Jonathan A. Bernstein, Avner Reshef, Gregor Porebski, Marcin Stobiecki, James R. Baker, Robyn J. Levy, Anurag Relan, Marc A. Riedl> ;The Journal of Allergy and Clinical Immunology. in Practice. 2015 May 1
52 citations
Recombinant human C1-esterase inhibitor relieves symptoms of hereditary angioedema attacks: phase 3, randomized, placebo-controlled trial
Marc A. Riedl, Jonathan A. Bernstein, Henry Li, Avner Reshef, William R. Lumry, Dumitru Moldovan, Henriette Farkas, Robyn J. Levy, James R. Baker, Yun Hardiman, Mark C...> ;Annals of Allergy, Asthma & Immunology. 2014 Feb 1
26 citations
Population pharmacokinetics of recombinant human C1 inhibitor in patients with hereditary angioedema.
Colm Farrell, Siobhan Hayes, Anurag Relan, Edwin S. van Amersfoort, Rienk Pijpstra, C. Erik Hack> ;British Journal of Clinical Pharmacology. 2013 Dec 1
44 citations
Efficacy and safety of recombinant C1 inhibitor for the treatment of hereditary angioedema attacks: a North American open-label study
Marc A. Riedl, Robyn J. Levy, Daniel Suez, Richard F. Lockey, James W. Baker, Anurag Relan, Bruce L. Zuraw> ;Annals of Allergy, Asthma & Immunology. 2013 Apr 1
14 citations
Immunosafety of Recombinant Human C1-Inhibitor in Hereditary Angioedema: Evaluation of IgE Antibodies
C. Erik Hack, Anurag Relan, Aartie Baboeram, Beatrijs Oortwijn, Serge A. Versteeg, Ronald van Ree, Rienk Pijpstra> ;Clinical Drug Investigation. 2013 Mar 6
33 citations
Recombinant human C1 inhibitor for the prophylaxis of hereditary angioedema attacks: a pilot study.
Avner Reshef, Dumitru Moldovan, Krystyna Obtułowicz, Iris Leibovich, Eniko Mihaly, S. Visscher, Anurag Relan> ;Allergy. 2013 Jan 1
Immunogenicity assessment of recombinant human c1-inhibitor: an integrated analysis of clinical studies.
Hack CE Mannesse M Baboeram A Oortwijn B Relan A > ;BioDrugs . 2012 Oct 1
19 citations
Clinical impact of peripheral attacks in hereditary angioedema patients.
Andy Kusuma, Anurag Relan, André C. Knulst, Dumitru Moldovan, Bruce L. Zuraw, Marco Cicardi, Robyn J. Levy, Jan H. Nuijens, C. Erik Hack> ;The American Journal of Medicine. 2012 Sep 1
18 citations
Content validity of visual analog scales to assess symptom severity of acute angioedema attacks in adults with hereditary angioedema: an interview study.
Carolyn Vivienne McMillan, Jane Speight, Anurag Relan, Luca Bellizzi, Gerald Haase, Marco Cicardi> ;The Patient. 2012 Aug 24
26 citations
Recombinant C1-inhibitor: effects on coagulation and fibrinolysis in patients with hereditary angioedema.
Anurag Relan, Kamran Bakhtiari, Edwin S. van Amersfoort, Joost C. M. Meijers, C. Erik Hack> ;Biodrugs. 2012 Aug 16
Join now to see all

Journal Articles

A Review of Hereditary Angioedema and Recombinant Human C1-Inhibitor Treatment
Bork K, Triggiani M, Caballero T, Relan A, European Gastroenterology and Hepatology Review

Press Mentions

Pharming Appoints Anurag Relan as Chief Medical Officer and Robert Friesen as Chief Scientific OfficerJune 17th, 2021
Pharming Announces First Patient Enrolled in Phase III Clinical Trial of Leniolisib for the Treatment of APDS in JapanAugust 10th, 2023